Emily H Cheng


Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA


  1. Liu H, Westergard T, Cashen A, Piwnica Worms D, Kunkle L, Vij R, et al. Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4. Cancer Cell. 2014;25:530-42 pubmed publisher
    ..Hence, feasible strategies to treat cancer-type and oncogene-specific cancers can be improvised through harnessing inherent tumor suppression properties of individual oncogenic fusions. ..
  2. Nargund A, Pham C, Dong Y, Wang P, Osmangeyoglu H, Xie Y, et al. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma. Cell Rep. 2017;18:2893-2906 pubmed publisher
    ..Our study reports a physiological preclinical ccRCC mouse model that recapitulates somatic mutations in human ccRCC and provides mechanistic and therapeutic insights into PBRM1 mutated subtypes of human ccRCC. ..
  3. Wang G, Tu H, Dong Y, Skanderup A, Wang Y, Takeda S, et al. ?Np63 Inhibits Oxidative Stress-Induced Cell Death, Including Ferroptosis, and Cooperates with the BCL-2 Family to Promote Clonogenic Survival. Cell Rep. 2017;21:2926-2939 pubmed publisher
    ..Our findings highlight the need for a simultaneous blockade of apoptosis and oxidative stress to promote long-term cellular well-being. ..